17:10:24 EST Tue 28 Nov 2023
Enter Symbol
or Name

Login ID:
Zentek Ltd
Symbol ZEN
Shares Issued 100,988,919
Close 2023-09-20 C$ 1.76
Recent Sedar Documents

Zentek to hold 2023 AGM Oct. 5 in Guelph

2023-09-21 11:59 ET - News Release

Dr. Francis Dube reports


Zentek Ltd.'s 2023 annual general and special meeting will be held on Thursday, Oct. 5, at 4 p.m. at the Delta Hotel in Guelph, Ont. Capacity may be limited, and attendees must register by e-mail at info@zentek.com. The meeting will be live streamed for those who cannot attend in person at the time of the AGM.

"We look forward to meeting our shareholders once again to discuss the company's achievements in the last year, the direction of the company going forward, answering shareholder questions, and to vote on important matters that will allow the board and management team to best move the company forward," said Francis Dube, chairman and chief operating officer for Zentek.

The management information circular has been mailed to shareholders of record on Friday, Aug. 25. Shareholders will be asked to vote on the following items:

  • To appoint BDO as the auditor of the company for the ensuing year and to authorize the directors to fix its remuneration;
  • To elect the directors of the company for the ensuing year;
  • To consider and, if deemed advisable, to pass an ordinary resolution approving the adoption of the company's omnibus long-term incentive plan;
  • To transact such other business as may properly come before the meeting or any adjournments or postponements thereof.

The nature of the business to be transacted at the meeting is described in further detail in the management information circular of the company under the section entitled "matters to be acted upon," which was sent to shareholders commencing on or around Sept. 5, 2023.

The company is pleased to announce John Snisarenko, BSc, MBA, is included in the circular as a proposed new director. Mr. Snisarenko is a senior executive with 35 years of specialty pharmaceutical, biologics, medical device and commercialization experience spanning from start-up to large pharma/biotech. Zentek believes Mr. Snisarenko will bring significant value to the board of directors as the company moves forward with the Aptamer platform, especially for the therapeutic market.

About Zentek Ltd.

Zentek is an ISO 13485:2016 certified intellectual property technology company focused on the research, development and commercialization of novel products seeking to give the company's commercial partners a competitive advantage by making their products better, safer and greener.

We seek Safe Harbor.

© 2023 Canjex Publishing Ltd. All rights reserved.